Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer

Mohamadkhani, Ashraf; Naderi, Elnaz; Sharafkhah, Maryam; Fazli, Hamid Reza; Moradzadeh, Malihe; Pourshams, Akram
January 2013
Journal of Oncology;2013, p1
Academic Journal
The TP53 gene encodes tumor protein p53 which play a major role in the etiology of pancreatic cancer. The important role of codon 249 of TP53 for binding of p53 to its sequence-specific consensus site in DNA has been revealed by crystallography's studies, and mutation at this codon was detected in the plasma of some human cancers. The TP53 Mut assessor software within the International Agency for Research on Cancer (IARC) TP53 Database was performed to evaluate every possible mutation at codon 249. DNA was extracted from the plasma of 133 pancreatic cancer patients and 85 noncancer-bearing individuals. Exon 7 in TP53 was amplified, and mutation at R249 was identified by the endonuclease cleavage of Haelll. The group of patients showed a frequency of 11% (22 of 133 samples) R249 mutation compared to 3.5% (3 of 85 samples) in the group of control which was significant (P = 0.03). This mutation demonstrated statistically significant association with pancreatic cancer risk in unadjusted odds ratio (OR: 3.74, 95% CI: 1.1-13.2; P = 0.041); however when adjusted for confounding factors, it was marginally significant because of lower control samples. These findings demonstrate that mutation at R249 of TP53 can be considered for increasing risk of pancreatic cancer that needs more research.


Related Articles

  • TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. Gillet, Emeline; Alentorn, Agusti; Doukouré, Brahima; Mundwiller, Emeline; Thuij, Hinke; Reijneveld, Jaap; Medina, José; Liou, Amélie; Marie, Yannick; Mokhtari, Karima; Hoang-Xuan, Khê; Sanson, Marc; Delattre, Jean-Yves; Idbaih, Ahmed // Journal of Neuro-Oncology;Jun2014, Vol. 118 Issue 1, p131 

    TP53 is a pivotal gene frequently mutated in diffuse gliomas and particularly in astrocytic tumors. The majority of studies dedicated to TP53 in gliomas were focused on mutational hotspots located in exons 5-8. Recent studies have suggested that TP53 is also mutated outside the classic...

  • Mutational spectra of human cancer. Pfeifer, Gerd P.; Besaratinia, Ahmad // Human Genetics;Jun2009, Vol. 125 Issue 5/6, p493 

    The purpose of this review is to summarize the evidence that can be used to reconstruct the etiology of human cancers from mutations found in tumors. Mutational spectra of the tumor suppressor gene p53 (TP53) are tumor specific. In several cases, these mutational spectra can be linked to...

  • Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Thornton, Patrick D.; Gruszka-Westwood, Alicja M.; Hamoudi, Rifat A.; Atkinson, Shayne; Kaczmarek, Pawel; Morilla, Ricardo M.; Hilditch, Benjamin L.; A'Hern, Roger; Matutes, Estella; Catovsky, Daniel // Hematology Journal;2004, Vol. 5 Issue 1, p47 

    Abnormalities of TP53 in chronic lymphocytic leukaemia (CLL) correlate with aggressive disease and transformation. We studied 115 patients with CLL including 90 untreated, 25 with heavily pretreated/refractory CLL using fluorescent in situ hybridisation (FISH) to detect allelic loss at...

  • Mutation analysis of the MDM4 gene in German breast cancer patients. Reincke, Scarlett; Govbakh, Lina; Wilhelm, Bettina; Haiyan Jin; Bogdanova, Natalia; Bremer, Michael; Karstens, Johann H.; Dörk, Thilo // BMC Cancer;2008, Vol. 8, Special section p1 

    Background: MDM4 is a negative regulator of p53 and cooperates with MDM2 in the cellular response to DNA damage. It is unknown, however, whether MDM4 gene alterations play some role in the inherited component of breast cancer susceptibility. Methods: We sequenced the whole MDM4 coding region and...

  • A half-site of the p53-binding site on the keratin 14 promoter is specifically activated by p63. Cai, Bi-He; Chao, Chung-Faye; Lu, Mei-Hua; Lin, Hwang-Chi; Chen, Jang-Yi // Journal of Biochemistry;Jul2012, Vol. 152 Issue 1, p99 

    Three members of p53 family, p53, p63 and p73, can transactivate their specific target genes through a p53 consensus sequence-binding motif which consists with direct repeats of PuPuPuC(T/A)(T/A)GPyPyPy as a whole-site of p53-binding site. p63, an epidermal stem cells marker, can regulate...

  • PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73. Rökaeus, N; Shen, J; Eckhardt, I; Bykov, V J N; Wiman, K G; Wilhelm, M T // Oncogene;12/9/2010, Vol. 29 Issue 49, p6442 

    The low molecular weight compound PRIMA-1 and the structural analog PRIMA-1MET, also named APR-246, reactivate mutant p53 through covalent binding to the core domain and induce apoptosis in tumor cells. Here, we asked whether PRIMA-1MET/APR-246 can rescue mutant forms of the p53 family members...

  • Correction: Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma. null, null // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    No abstract available.

  • TP53 gene mutations predicted OS in dif use large B-cell lymphoma.  // Hem/Onc Today;12/25/2008, Vol. 9 Issue 23, p34 

    The article reports on a study which found that mutations in the DNA-binding domains of the tumor suppressor gene TP53 are independently predictive of overall survival (OS) in patients with diffuse large B-cell lymphoma. TP53 plays an important role in regulating the cell cycle, cell...

  • Prevalence of the TP53 p.R337H Mutation in Breast Cancer Patients in Brazil. Giacomazzi, Juliana; Graudenz, Marcia S.; Osorio, Cynthia A. B. T.; Koehler-Santos, Patricia; Palmero, Edenir I.; Zagonel-Oliveira, Marcelo; Michelli, Rodrigo A. D.; Neto, Cristovam Scapulatempo; Fernandes, Gabriela C.; Achatz, Maria Isabel W. S.; Martel-Planche, Ghyslaine; Soares, Fernando A.; Caleffi, Maira; Goldim, José Roberto; Hainaut, Pierre; Camey, Suzi A.; Ashton-Prolla, Patricia // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Germline TP53 mutations predispose individuals to multiple cancers and are associated with Li-Fraumeni/Li-Fraumeni-Like Syndromes (LFS/LFL). The founder mutation TP53 p.R337H is detected in 0.3% of the general population in southern Brazil. This mutation is associated with an increased risk of...


Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics